Could a plasma treatment beat serum for aniridia eye damage?
NCT ID NCT05400590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two treatments made from patients' own blood—autologous serum and growth factor-rich plasma—to see which helps heal the cornea better in people with aniridia, a rare eye condition. Researchers will test these treatments on corneal cells in the lab, using blood and cell samples from 24 participants (12 with aniridia and 12 healthy controls). The goal is to find a way to reduce scarring and improve healing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- growth factor-rich plasma and autologous serum
- What this could lead to
- If successful, this could point toward a better treatment for corneal clouding in aniridia patients, potentially reducing scarring.
- What could go wrong
- This is a small, early-stage lab study with only 24 participants, so results may not translate to real-world healing or benefit all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANIRIDIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Fondation A. de Rothschild
RECRUITINGParis, 75019, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.